Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic

Switching to rIX‐FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in contexts of limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz‐Jordán, Bolívar Luis, Cebanu, Tamara, García Barcenilla, Sara, Álvarez‐Román, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683034/
https://www.ncbi.nlm.nih.gov/pubmed/38033685
http://dx.doi.org/10.1002/ccr3.8180
_version_ 1785151102690263040
author Díaz‐Jordán, Bolívar Luis
Cebanu, Tamara
García Barcenilla, Sara
Álvarez‐Román, Maria Teresa
author_facet Díaz‐Jordán, Bolívar Luis
Cebanu, Tamara
García Barcenilla, Sara
Álvarez‐Román, Maria Teresa
author_sort Díaz‐Jordán, Bolívar Luis
collection PubMed
description Switching to rIX‐FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in contexts of limited mobility and overloaded healthcare services.
format Online
Article
Text
id pubmed-10683034
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106830342023-11-30 Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic Díaz‐Jordán, Bolívar Luis Cebanu, Tamara García Barcenilla, Sara Álvarez‐Román, Maria Teresa Clin Case Rep Case Report Switching to rIX‐FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in contexts of limited mobility and overloaded healthcare services. John Wiley and Sons Inc. 2023-11-28 /pmc/articles/PMC10683034/ /pubmed/38033685 http://dx.doi.org/10.1002/ccr3.8180 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Díaz‐Jordán, Bolívar Luis
Cebanu, Tamara
García Barcenilla, Sara
Álvarez‐Román, Maria Teresa
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
title Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
title_full Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
title_fullStr Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
title_full_unstemmed Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
title_short Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
title_sort real‐world experience of rix‐fp prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia b during the covid‐19 pandemic
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683034/
https://www.ncbi.nlm.nih.gov/pubmed/38033685
http://dx.doi.org/10.1002/ccr3.8180
work_keys_str_mv AT diazjordanbolivarluis realworldexperienceofrixfpprophylaxisatdosingintervalsofupto14daysinapediatricpatientwithhemophiliabduringthecovid19pandemic
AT cebanutamara realworldexperienceofrixfpprophylaxisatdosingintervalsofupto14daysinapediatricpatientwithhemophiliabduringthecovid19pandemic
AT garciabarcenillasara realworldexperienceofrixfpprophylaxisatdosingintervalsofupto14daysinapediatricpatientwithhemophiliabduringthecovid19pandemic
AT alvarezromanmariateresa realworldexperienceofrixfpprophylaxisatdosingintervalsofupto14daysinapediatricpatientwithhemophiliabduringthecovid19pandemic

Ejemplares similares